CLINICAL ROLE OF miRNA BIOMARKERS IN LARYNGEAL SQUAMOUS CELL CARCINOMA (LSCC): LITERATURE REVIEW

Abstract

IntroductionMalignant transformations may result from gene dysregulation caused by genetic and epigenetic modifications. The use of miRNAs to treat cancer depends on the downregulation or upregulation of the miRNAs responsible for carcinogenesis (proliferation, angiogenesis, invasion, metastasis), providing the opportunity to suppress tumors. The purpose of this review is to list miRNAs identified so far as biomarkers in laryngeal squamous cell carcinoma (LSCC). This listing may help in predicting the evolution of miRNAs and developing anti-miRNAs and miRNA-mimics as anti-cancer therapies.Material and methodsRelevant publications from 2008 to 2022 were retrieved from the PubMed and Google Scholar databases, using the key words miRNA (PubMed – 149,294 results; Google Scholar – 205,000 results), laryngeal squamous cell carcinoma (PubMed – 33,191 results; Google Scholar – 17,900 results), laryngeal squamous cell carcinoma biomarkers (PubMed – 6249 results; Google Scholar – 18,000 results), laryngeal squamous cell carcinoma miRNA (PubMed – 1338 results; Google Scholar – 17,500 results). Eventually 51 papers were selected for review.ResultsWe identified 51 studies which have detected miRNA-based biomarkers for LSCC, and they are broadly reviewed here.ConclusionsThe identified laryngeal squamous cell-specific miRNA biomarkers appear to be promising for the detection, predicted course, and treatment of LSCC.